153 related articles for article (PubMed ID: 33340821)
1. Drug retention rates of biological agents in adult onset Still's disease.
Campochiaro C; Farina N; Tomelleri A; De Luca G; Baldissera E; Cavalli G; Dagna L
Semin Arthritis Rheum; 2021 Feb; 51(1):1-6. PubMed ID: 33340821
[TBL] [Abstract][Full Text] [Related]
2. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis.
Campochiaro C; Tomelleri A; Sartorelli S; Cavalli G; De Luca G; Baldissera E; Dagna L
Semin Arthritis Rheum; 2020 Jun; 50(3):509-514. PubMed ID: 32088012
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?
Dall'Ara F; Frassi M; Tincani A; Airò P
Clin Rheumatol; 2016 Aug; 35(8):2117-2123. PubMed ID: 26758435
[TBL] [Abstract][Full Text] [Related]
4. Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
Ruscitti P; Cipriani P; Liakouli V; Iacono D; Pantano I; Caso F; Perosa F; Atzeni F; Cantatore FP; Scarpa R; Ciccia F; Giacomelli R
Rheumatol Int; 2020 Jan; 40(1):107-113. PubMed ID: 31263993
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab in adult-onset Still's disease: the Israeli experience.
Elkayam O; Jiries N; Dranitzki Z; Kivity S; Lidar M; Levy O; Ablin J; Abu-Shakra M; Savargyl-Maman H; Padova H; Caspi D; Rosner I
J Rheumatol; 2014 Feb; 41(2):244-7. PubMed ID: 24429168
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry.
Sota J; Vitale A; Lopalco G; Pereira RMR; Giordano HF; Antonelli IPB; Makowska J; Brzezińska O; Lewandowska-Polak A; Ruscitti P; Cipriani P; Cola ID; Govoni M; Ruffili F; Sfikakis PP; Laskari K; Ragab G; Hussein MA; Gentileschi S; Gaggiano C; La Torre F; Maier A; Emmi G; Marino A; Ciccia F; Sfriso P; Maggio MC; Bartoloni E; Lomater C; Hegazy MT; Tektonidou M; Dagostin MA; Opinc A; Sebastiani GD; Giacomelli R; Giudice ED; Olivieri AN; Tufan A; Kardas RK; Nuzzolese R; Cardinale F; Więsik-Szewczyk E; Veronica P; Tarsia M; Iannone F; Della Casa F; Fabiani C; Frediani B; Balistreri A; Rigante D; Cantarini L
Semin Arthritis Rheum; 2022 Dec; 57():152089. PubMed ID: 36063578
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
9. Systematic review on the use of biologics in adult-onset still's disease.
Fautrel B; Patterson J; Bowe C; Arber M; Glanville J; Mealing S; Canon-Garcia V; Fagerhed L; Rabijns H; Giacomelli R
Semin Arthritis Rheum; 2023 Feb; 58():152139. PubMed ID: 36442231
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of biological agents in adult-onset Still's disease.
Cavalli G; Franchini S; Aiello P; Guglielmi B; Berti A; Campochiaro C; Sabbadini MG; Baldissera E; Dagna L
Scand J Rheumatol; 2015; 44(4):309-14. PubMed ID: 25656459
[TBL] [Abstract][Full Text] [Related]
11. The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study.
Nishina N; Kaneko Y; Kameda H; Takeuchi T
Mod Rheumatol; 2015 May; 25(3):401-4. PubMed ID: 25401229
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases.
Song ST; Kim JJ; Lee S; Kim HA; Lee EY; Shin KC; Lee JH; Lee KH; Choi ST; Cha HS; Yoo DH
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S64-S71. PubMed ID: 27462914
[TBL] [Abstract][Full Text] [Related]
13. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
14. Anakinra for the treatment of adult-onset Still's disease.
Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options and safety considerations when treating adult-onset Still's disease.
Cavalli G; Farina N; Campochiaro C; Baldissera E; Dagna L
Expert Opin Drug Saf; 2020 Dec; 19(12):1549-1558. PubMed ID: 33078630
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.
Park EH; Lee EY; Shin K; Kim HA
Rheumatol Int; 2020 May; 40(5):791-798. PubMed ID: 31598752
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.
Sakai R; Nagasawa H; Nishi E; Okuyama A; Takei H; Kurasawa T; Kondo T; Nishimura K; Shirai Y; Ito T; Kameda H; Takeuchi T; Amano K
Clin Rheumatol; 2012 Mar; 31(3):569-74. PubMed ID: 22215118
[TBL] [Abstract][Full Text] [Related]
20. Adult-onset still's disease and treatment results with tocilizumab.
Kır S; Özgen M; Zontul S
Int J Clin Pract; 2021 Mar; 75(3):e13936. PubMed ID: 33332679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
